Announced Tue, 13 Oct, 2026 · 21:35 IST

Quarterly dematerialization certificate filed with BSE for Q2 FY27

Compliance View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.1%Reaction day

₹228.65

prior close

₹238.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.7%-2.8% vs market

Pharmaceuticals peers, median of 172sector+0.0%-2.1% vs sector

On the reaction day the stock moved 2.8 pts less than Nifty Microcap 250 and 2.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.1+0.7-2.8+0.0-2.1

Next day

-3.7-1.0-2.8-0.8-3.0

-0.8-0.3-0.5-0.6-0.2

+2.6-1.9+4.6-1.9+4.5

+0.0-4.5+4.5-3.5+3.6

-2.9-5.5+2.5-4.4+1.5

+1.0-7.3+8.3-4.4+5.4

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Auro Laboratories has submitted a routine certificate to BSE under SEBI Regulation 74(5) for the quarter ended September 30, 2026. The filing, signed by RTA Purva Sharegistry, confirms details of share certificates dematerialized between July and September 2026, listing small lots of 100 shares each converted from physical to demat form by individual shareholders. This is a standard quarterly compliance submission with no business or financial content.

Likely market impact

No impact on shareholders or stock price. Routine regulatory compliance filing with no material information.